The company has switched from pursuing a counterpulsation technology to focusing on a fully implantable neuromodulation device, and is now directing its full attention to the recently acquired Aquadex FlexFlow ultrafiltration system for heart failure, all in a period of about three-to-four months.

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.